The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.
The US Food and Drug Administration has issued new labeling changes for all approved testosterone replacement therapy ...
Marius Pharmaceuticals, a pharmaceutical company dedicated to developing innovative therapies for testosterone deficiency, has partnered with Duke University School of Medicine to explore the ...
In September 2024, Marius Pharmaceuticals proactively submitted ... has reaffirmed the safety and benefits of testosterone therapy. A global consensus has emerged on testosterone’s ...
Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...
RALEIGH, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals ... the global healthcare system. For more information, please visit www.mariuspharma.com. About KYZATREX® (testosterone ...
Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...
Recent health updates include the U.S. participating in WHO meetings, UK approval of a Moderna vaccine, a Texas measles ...
Lipocine Inc. , a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug ...
Among these was a product called VIP Go Rhino Gold 69K from a sex shop in Quebec City, Quebec; Alien 2 Power Platinum 11000 ...
Serum testosterone (T) recovery to normal levels ... When considering the global hazard ratio, a significantly lower risk for death favored patients recovering T (hazard ratio, 0.54).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback